Campese, V. M., Callahan, A., Rudolph, A. E., Messig, M., Amarenco, P., Goldstein, L. B., … Welch, K. M. (2007). Effect of high-dose atorvastatin on changes in renal function: A secondary analysis of the stroke prevention by aggressive reduction of cholesterol levels (SPARCL) trial. In CIRCULATION (Vol. 116, pp. 471–471). Orlando, FL: LIPPINCOTT WILLIAMS & WILKINS.

Campese, Vito M., Alfred Callahan, Amy E. Rudolph, Michael Messig, Pierre Amarenco, Larry B. Goldstein, Michael Hennerici, Henrik Sillesen, Justin A. Zivin, and K. M. Welch. “Effect of high-dose atorvastatin on changes in renal function: A secondary analysis of the stroke prevention by aggressive reduction of cholesterol levels (SPARCL) trial.” In CIRCULATION, 116:471–471. LIPPINCOTT WILLIAMS & WILKINS, 2007.

Campese VM, Callahan A, Rudolph AE, Messig M, Amarenco P, Goldstein LB, et al. Effect of high-dose atorvastatin on changes in renal function: A secondary analysis of the stroke prevention by aggressive reduction of cholesterol levels (SPARCL) trial. In: CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 471–471.

Campese, Vito M., et al. “Effect of high-dose atorvastatin on changes in renal function: A secondary analysis of the stroke prevention by aggressive reduction of cholesterol levels (SPARCL) trial.” CIRCULATION, vol. 116, no. 16, LIPPINCOTT WILLIAMS & WILKINS, 2007, pp. 471–471.

Campese VM, Callahan A, Rudolph AE, Messig M, Amarenco P, Goldstein LB, Hennerici M, Sillesen H, Zivin JA, Welch KM. Effect of high-dose atorvastatin on changes in renal function: A secondary analysis of the stroke prevention by aggressive reduction of cholesterol levels (SPARCL) trial. CIRCULATION. LIPPINCOTT WILLIAMS & WILKINS; 2007. p. 471–471.